FDA Approval: Zidesamtinib and ROS1 NSCLC

Patients with ROS1-positive NSCLC have a new treatment option following the FDA approval of zidesamtinib for those previously treated with a ROS1 tyrosine kinase inhibitor. In this episode, Dr. Stephen Liu, Dr. Alexander Drilon, and Dr. Rosario Charo Garcia Campelo discuss the ARROS1 trial results, the drug's efficacy and safety profile, CNS activity, and where zidesamtinib may fit into current and future treatment strategies for ROS1-positive lung cancer.

Guests:

Alexander Drilon, MD

Chief, Early Drug Development Service

Attending Physician, Thoracic Oncology Service

Memorial Sloan Kettering Cancer Center

Professor, Weill Cornell Medical College

Rosario Charo Garcia Campelo, MD

Head of Medical Oncology and Thoracic Tumor Unit, Chair, University Hospital

Head of the Oncology Research Group, Biomedical Research Institute A Coruna Spain